SHP1 Cancer Research Results

SHP1, Src Homology region 2 domain-containing Phosphatase-1: Click to Expand ⟱
Source:
Type:
SHP1 is a non-receptor protein tyrosine phosphatase primarily encoded by the gene PTPN6.
Immune Checkpoint Brake, Tumor Suppressor Signaling, and Immune Evasion

– In blood cancers such as leukemia and lymphoma, altered SHP1 expression (often downregulation) is frequently observed.
– Downregulation or loss of SHP1 is often associated with more aggressive disease phenotypes and poorer prognosis.
Direction of Regulation in Cancer 
Two distinct, context-specific directions:
A. Tumor Cells (especially hematologic malignancies): DOWNREGULATED
-Frequently silenced epigenetically (promoter methylation)
-Rarely mutated; loss is regulatory
-Results in unchecked growth and survival signaling

B. Immune Cells within the Tumor Microenvironment: FUNCTIONALLY UPREGULATED
-Actively recruited by inhibitory receptors
-Suppresses T-cell, NK-cell, and myeloid anti-tumor responses
-Promotes immune evasion

This duality is critical to interpret SHP1 correctly.

When SHP1 is lost in tumor cells:
-JAK–STAT signaling becomes hyperactive
-Growth and survival pathways escape negative feedback
-Cells gain a proliferative and survival advantage


Scientific Papers found: Click to Expand⟱
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, antioxidant, anti-inflammatory, hepatoprotective, neuroprotective
*Inflam↓, inhibitory effect of chrysin on inflammation and oxidative stress is also important in Parkinson’s disease
*hepatoP↑,
*neuroP↑,
*BioAv↓, Accumulating data demonstrates that poor absorption, rapid metabolism, and systemic elimination are responsible for poor bioavailability of chrysin in humans that, subsequently, restrict its therapeutic effects
*cardioP↑, cardioprotective [69], lipid-lowering effect [70]
*lipidLev↓,
*RenoP↑, Renoprotective
*TNF-α↓, chrysin reduces levels of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2).
*IL2↓,
*PI3K↓, induction of the PI3K/Akt signaling pathway by chrysin contributes to a reduction in oxidative stress and inflammation during cerebral I/R injury
*Akt↓,
*ROS↓,
*cognitive↑, Chrysin (25, 50, and 100 mg/kg) improves cognitive capacity, inflammation, and apoptosis to ameliorate traumatic brain injury
eff↑, chrysin and silibinin is beneficial in suppressing breast cancer malignancy via decreasing cancer proliferation
cycD1/CCND1↓, chrysin and silibinin induced cell cycle arrest via down-regulation of cyclin D1 and hTERT
hTERT/TERT↓,
VEGF↓, Administration of chrysin is associated with the disruption of hypoxia-induced VEGF gene expression
p‑STAT3↓, chrysin is capable of reducing STAT3 phosphorylation in hypoxic conditions without affecting the HIF-1α protein level.
TumMeta↓, chrysin is a potent agent in suppressing metastasis and proliferation of breast cancer cells during hypoxic conditions
TumCP↓,
eff↑, combination therapy of breast cancer cells using chrysin and metformin exerts a synergistic effect and is more efficient compared to chrysin alone
eff↑, combination of quercetin and chrysin reduced levels of pro-inflammatory factors, such as IL-1β, Il-6, TNF-α, and IL-10, via NF-κB down-regulation.
IL1β↓,
IL6↓,
NF-kB↓,
ROS↑, after chrysin administration, an increase occurs in levels of ROS that, subsequently, impairs the integrity of the mitochondrial membrane, leading to cytochrome C release and apoptosis induction
MMP↓,
Cyt‑c↑,
Apoptosis↑,
ER Stress↑, in addition to mitochondria, ER can also participate in apoptosis
Ca+2↑, Upon chrysin administration, an increase occurs in levels of ROS and cytoplasmic Ca2+ that mediate apoptosis induction in OC cells
TET1↑, In MKN45 cells, chrysin promotes the expression of TET1
Let-7↑, Chrysin is capable of promoting the expression of miR-9 and Let-7a as onco-suppressor factors in cancer to inhibit the proliferation of GC cells
Twist↓, Down-regulation of NF-κB, and subsequent decrease in Twist/EMT are mediated by chrysin administration, negatively affecting cervical cancer metastasis
EMT↓,
TumCCA↑, nduction of cell cycle arrest and apoptosis via up-regulation of caspase-3, caspase-9, and Bax are mediated by chrysin
Casp3↑,
Casp9↑,
BAX↑,
HK2↓, Chrysin administration (15, 30, and 60 mM) reduces the expression of HK-2 in hepatocellular carcinoma (HCC) cells to impair glucose uptake and lactate production.
GlucoseCon↓,
lactateProd↓,
Glycolysis↓, In addition to glycolysis metabolism impairment, the inhibitory effect of chrysin on HK-2 leads to apoptosis
SHP1↑, upstream modulator of STAT3 known as SHP-1 is up-regulated by chrysin
N-cadherin↓, Furthermore, N-cadherin and E-cadherin are respectively down-regulated and up-regulated upon chrysin administration in inhibiting melanoma invasion
E-cadherin↑,
UPR↑, chrysin substantially diminishes survival by ER stress induction via stimulating UPR, PERK, ATF4, and elF2α
PERK↑,
ATF4↑,
eIF2α↑,
RadioS↑, Irradiation combined with chrysin exerts a synergistic effect
NOTCH1↑, Irradiation combined with chrysin exerts a synergistic effect
NRF2↓, in reducing Nrf2 expression, chrysin down-regulates the expression of ERK and PI3K/Akt pathways—leading to an increase in the efficiency of doxorubicin in chemotherapy
BioAv↑, chrysin at the tumor site by polymeric nanoparticles leads to enhanced anti-tumor activity, due to enhanced cellular uptake
eff↑, Chrysin- and curcumin-loaded nanoparticles significantly promote the expression of TIMP-1 and TIMP-2 to exert a reduction in melanoma invasion

6285- DL,    Limonin inhibits angiogenesis and metastasis of human breast cancer cells by suppressing the VEGFR2/IGFR1-mediated STAT3 signaling pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
VEGF↓, Limonin dose-dependently inhibited the vascular endothelial growth factor (VEGF)
*STAT3↓, suppressing constitutive STAT3 activation in human umbilical vein endothelial cells.
TumCP↓, inhibited VEGF-induced endothelial cell proliferation, migration and tubular-structure formation in vitro and markedly reduced VEGF-triggered neovascularization in mouse matrigel plugs in vivo.
TumMeta↓, remarkable suppression of tumor metastasis by decreasing the phosphorylation of insulin growth factor receptor 1-mediated STAT3 and the expression levels of its downstream members MMP-9 and VEGF in breast cancer cells.
p‑STAT3↓,
MMP9↓,
SHP1↑, limonin increased the levels of the negative STAT3 regulator SHP-1 in breast cancer cells.
angioG↓, Limonin is a promising anti-angiogenic and anti-metastatic candidate compound

5225- EMD,    Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
STAT3↓, Emodin suppressed STAT3 activation in a dose- and time-dependent manner in HCC cells
Akt↓, Emodin inhibits IL-6-inducible Akt phosphorylation in HCC cells
cSrc↓, Emodin suppresses constitutive activation of c-Src
JAK1↓, Emodin suppresses constitutive activation of JAK1 and JAK2 in HCC cells
JAK2↓,
SHP1↑, Emodin induces the expression of SHP-1 in HCC cells
cycD1/CCND1↓, Emodin down-regulates the expression of cyclin D1, Bcl-2, Bcl-xL, Mcl-1, survivin and VEGF
Bcl-2↓,
Bcl-xL↓,
Mcl-1↓,
survivin↓,
VEGF↓,
TumCP↓, Emodin inhibits the proliferation of HCC cells in a dose- and time-dependent manner
Casp3↑, Emodin activates caspase-3 and causes PARP cleavage
cl‑PARP↑,
ChemoSen↑, Emodin potentiates the apoptotic effect of doxorubicin and paclitaxel in HepG2 cells
XIAP↓, The reduction in survival markers like Bcl-2, Bcl-xL, XIAP and survivin was similar for HepG2 cells treated with emodin

7244- Gink,    Ginkgetin Blocks Constitutive STAT3 Activation and Induces Apoptosis through Induction of SHP-1 and PTEN Tyrosine Phosphatases
- in-vitro, Lung, A549 - in-vitro, Laryn, FaDu
p‑STAT3↓, We found that ginkgetin clearly suppressed constitutive phosphorylation of STAT3 through inhibition of the activation of upstream JAK1 and c-Src kinases and nuclear translocation of STAT3 on both A549 and FaDu cells.
JAK1↓,
Src↓,
SHP1↑, Overall, ginkgetin abrogates STAT3 signaling pathway through induction of SHP-1 and PTEN proteins, thus attenuating STAT3 phosphorylation and tumorigenesis.
PTEN↑,

7260- Gink,    Ginkgetin: A natural biflavone with versatile pharmacological activities
- Review, Var, NA - Review, Stroke, NA - Review, AD, NA
*AntiCan↑, Ginkgetin (GK), a natural non-toxic biflavone, has been shown to exhibit anti-cancer, anti-inflammatory, anti-microbial, anti-adipogenic, and neuroprotective activities.
*Inflam↓,
*AntiBio↑,
*neuroP↑,
*TumCCA↑, GK combats cancer progression by arresting cell cycle, inducing apoptosis, stimulating autophagy, and targeting many deregulated signaling pathways such as JAK/STAT and MAPKs.
Apoptosis↑,
TumAuto↑,
iNOS↓, GKhalts inflammation mediators like interleukins, iNOS, COX-2, PGE2, NF-κB, and acts as an inhibitor of PLA2
COX2/PTGS2↓,
PGE2↓,
NF-kB↓,
PLA2↓,
*neuroP↑, GK shows strong neuroprotection against oxidative stress-promoted cell death, inhibits cerebral micro-hemorrhage, decreases neurologic deficits, and halts apoptosis of neurons
*Stroke↓, in cerebral ischemia rat model, GK significantly improved I/R-stimulated neurological deficit scores
*AntiFungal↓, GK also acts as anti-fungal, anti-viral, anti-bacterial, leishmanicidal and anti-plasmodial agent.
*Bacteria↓,
Bcl-xL↓, steosarcoma cells, GK significantly suppressed the levels of B-cell lymphoma-extra-large (Bcl-xL) and B-cell lymphoma 2 (Bcl-2) proteins while significantly elevated levels of caspase-9 and -3 along with cleaved poly ADP ribose polymerase (PARP)
Bcl-2↓,
Casp9↑,
Casp3↑,
cl‑PARP↑,
IL6↓, GK selectively repressed the proliferation of prostate tumor via repressing interleukin 6 (IL-6)-induced as well as constitutive activation of STAT3
STAT3↓,
JAK1↓, GK abrogated the constitutive activation of both Src and JAK1 kinases which in turn halted STAT3 activation in FaDu and A549 cells.
survivin↓, suppressed its target genes including survivin, cyclooxygenase-2 (COX-2), inhibitor of apoptosis protein-1 (IAP-1), Bcl-xL, Bcl-2, matrix metalloproteinase 2 and 9 (MMP-2 and -9)
COX2/PTGS2↓,
IAP1↓,
MMP2↓,
MMP9↓,
PTEN↑, GK prompted the mRNA and protein expression of phosphatase and tensin homolog (PTEN) and SHP-1 which also paly role in STAT3 activation
SHP1↑,
eff↑, When GK is applied in combination with resveratrol, they synergistically act to suppress endothelial cell proliferation, migration, and reactive oxygen species (ROS) production as compared to mono drug
TumVol↓, GK decreased the weight and volume of tumor by 67.4% and 65.6%, respectively in the DU-145 xenografted mice model as compared to control and no toxic effect towards normal cells had been observed
TumW↓,
*toxicity↓,
*ROS↓, mediated neuronal cell damage in vitro by reducing intracellular ROS and maintaining MMP

5160- PLB,  VitK3,    Plumbagin, Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization
- in-vitro, Melanoma, U266
STAT3↓, plumbagin inhibited both constitutive and IL-6-inducible STAT3 phosphorylation in multiple myeloma (MM) cells
cSrc↓, his correlated with the inhibition of c-Src, JAK1, and JAK2 activation
JAK1↓,
JAK2↓,
SHP1↑, plumbagin induced the expression of the protein tyrosine phosphatase, SHP-1;
cycD1/CCND1↓, downregulated the expression of STAT3-regulated cyclin D1, Bcl-xL, and VEGF, activated caspase-3, induced PARP cleavage, and increased the sub-G1 population of MM cells.
Bcl-xL↓,
VEGF↓,
Casp3↑,
cl‑PARP↑,
TumCCA↑,
ChemoSen↑, sensitization of STAT3 overexpressing cancers to chemotherapeutic agents.


Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PLA2↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

NRF2↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 2,   Bcl-xL↓, 3,   Casp3↑, 4,   Casp9↑, 2,   Cyt‑c↑, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   iNOS↓, 1,   Mcl-1↓, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

eIF2α↑, 1,   ER Stress↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 3,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   Let-7↑, 1,   NOTCH1↑, 1,   PTEN↑, 2,   SHP1↑, 6,   Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 3,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   E-cadherin↑, 1,   MMP2↓, 1,   MMP9↓, 2,   N-cadherin↓, 1,   TET1↑, 1,   TumCP↓, 3,   TumMeta↓, 2,   Twist↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↑, 1,   VEGF↓, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   IL1β↓, 1,   IL6↓, 2,   JAK1↓, 4,   JAK2↓, 2,   NF-kB↓, 2,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 2,   eff↑, 5,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

hTERT/TERT↓, 1,   IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,   TumW↓, 1,  
Total Targets: 66

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ROS↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

lipidLev↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,   STAT3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL2↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 3,   RenoP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↓, 1,   Bacteria↓, 1,  
Total Targets: 22

Scientific Paper Hit Count for: SHP1, Src Homology region 2 domain-containing Phosphatase-1
2 Ginkgetin
1 Chrysin
1 D-limonene
1 Emodin
1 Plumbagin
1 VitK3,menadione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1331  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page